Tech Transfer eNews Blog
University-Industry Engagement Advisor

U of Louisville licenses anti-cancer compound to Qualigen

By Jesse Schwartz
Published: July 18th, 2018

Medical device company Qualigen and the University of Louisville (UofL) have entered into a license agreement to commercialize a novel molecular-based compound that has shown promise as a cancer treatment, radio-sensitizing agent, and MRI contrasting agent.

Under the agreement, Qualigen will manage the development, regulatory approval and commercialization of anti-nucleolin agent-conjugated nanoparticles, developed at UofL. In return, the university will receive cash payments based on certain milestones and royalties based on future drug sales, as well as potential equity in Qualigen.

The licensed compound can be used to treat virtually any type of cancer, with several other potential applications including the direct delivery of other anti-cancer compounds to tumor cells, enhancement of radiation therapy and enhancement of tumor imaging. A key component of the compound, known as AS1411-GNP, has been tested on more than 100 patients. At least 7 patients showed long-lasting clinical responses where their cancers disappeared or shrunk, with no evidence of severe side effects.

“We are delighted to add AS1411-GNP to our portfolio of anticancer drug technologies,” says Michael S. Poirier, chairman, CEO and president of Qualigen. “This is a unique opportunity to continue development of a compound that has already undergone extensive preclinical characterization and shown promise in prior clinical studies.”

Allen Morris, director of the University of Louisville Office of Technology Transfer, comments, “We are excited to work with Qualigen on the product development of our nanoparticle-based drug to fight cancer. This is the kind of outcome we seek in our translational efforts — getting our research to market where it can benefit people.”

Source: Markets Insider

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment